Live Breaking News & Updates on Pharma Innovator|Page 4
Stay updated with breaking news from Pharma innovator. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(1) Exploratory biomarker analyses from an ongoing phase 1 study of Daiichi Sankyo Company, Limited s (hereafter, Daiichi Sankyo) patritumab deruxtecan, a HER3 directed DXd antibody drug conjugate (ADC), in patients with previously treated EGFR-mutated metastatic/unresectable non-small cell lung cancer (NSCLC) were highlighted in a poster presentation today at the IASLC 2020 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer. Lung cancer is the leading cause of cancer death among both men and women, and accounts for about one-fifth of all cancer deaths globally, with 80 to 85 percent classified as NSCLC. 1,2 For patients with metastatic disease, prognosis is particularly poor, as only 6 to 10 percent live beyond five years after diagnosis. ....
Press release content from Business Wire. The AP news staff was not involved in its creation. ENHERTU® Receives Prime Minister’s Award from the Japan Techno-Economics Society January 27, 2021 GMT Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that ENHERTU ® (trastuzumab deruxtecan), a HER2 directed antibody drug conjugate (ADC), received the Prime Minister’s Award at the 9 th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES). The Technology Management and Innovation Awards were established in 2012 with the objective of contributing to the development of the nation’s economy, social changes, and the promotion of a global competitive edge by widely introducing technological innovations originating in Japan. This year marks the 9 th year of the award. ....
Daiichi Sankyo Company, Limited: ENHERTU Receives Prime Minister s Award from the Japan Techno-Economics Society Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that ENHERTU (trastuzumab deruxtecan), a HER2 directed antibody drug conjugate (ADC), received the Prime Minister s Award at the 9 th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES). The Technology Management and Innovation Awards were established in 2012 with the objective of contributing to the development of the nation s economy, social changes, and the promotion of a global competitive edge by widely introducing technological innovations originating in Japan. This year marks the 9 th year of the award. ....
Press release content from Business Wire. The AP news staff was not involved in its creation. ENHERTU® Approved in the EU for the Treatment of HER2 Positive Metastatic Breast Cancer January 20, 2021 GMT Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU ® (trastuzumab deruxtecan) has been granted conditional approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2 based regimens. In Europe, approximately 531,000 cases of breast cancer in women are diagnosed annually, with an estimated one in five cases being HER2 positive. 1,2,3 The impact of the disease is significant, with breast cancer responsible for more than 141,000 deaths per year in Europe. 1 ....
Hits: 1063 First HER2 directed medicine approved for patients with gastric cancer in a decade TOKYO, Japan & MUNICH, Germany & BASKING RIDGE, NJ USA I January 15, 2021 I Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU ® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. In the U.S., gastric cancer is more frequently diagnosed in the advanced stage, with only approximately 5% of patients surviving five years. 1,2 Approximately one in five gastric cancers are HER2 positive. ....